Intec Pharma to Participate in the Oppenheimer Specialty Pharma Summit
JERUSALEM, October 6, 2017 /PRNewswire/ --
Intec Pharma Ltd. (NASDAQ and TASE: NTEC) today announced that management will participate in the Oppenheimer Specialty Pharma Summit to be held October 11, 2017 at the Sofitel Hotel in New York City.
Date: Wednesday, October 11, 2017
Venue: Sofitel New York Hotel
Format: One-on-One Meetings with Investors
Presenter: Jeffrey A. Meckler, Chief Executive Officer of Intec Pharma
The investor presentation will be posted to the Events section of the Company's website at http://www.intecpharma.com.
About Intec Pharma Ltd.
Intec Pharma is a clinical-stage biopharmaceutical company focused on developing drugs based on its proprietary Accordion Pill platform technology. The Company's Accordion Pill is an oral drug delivery system that is designed to improve the efficacy and safety of existing drugs and drugs in development by utilizing an efficient gastric retention and specific release mechanism. The Company's product pipeline includes two product candidates in clinical trial stages: Accordion Pill Carbidopa/Levodopa, or AP-CD/LD, which is being developed for the treatment of Parkinson's disease symptoms in advanced Parkinson's disease patients, and AP-CBD/THC, an Accordion Pill with the two primary cannabinoids contained in Cannabis sativa, cannabidiol (CBD) and tetrahydrocannabinol (THC), which is being developed for various indications including low back neuropathic pain and fibromyalgia.
Jeffrey A. Meckler
Chief Executive Officer
Intec Pharma Ltd.
SOURCE Intec Pharma Ltd.
Source: PR Newswire (October 6, 2017 - 7:00 AM EDT)